Cervical cancer: India launches vaccine against cervical cancer
Cervical cancer: According to SII, DCGI had approved the vaccination in July.
According to official sources, today i.e. on September 1, Serum Institute of India (SII) and Department of Biotechnology (DBT) will present India’s first locally manufactured quadrivalent Human Papillomavirus Vaccine (QHPV) against cervical cancer.
According to the Serum Institute of India, the Drug Controller General of India had approved the vaccination in July. According to the statement, Minister of State (Independent Charge) for Science and Technology Jitendra Singh will release the vaccine in Delhi.
The World Health Organization (WHO) estimates that India carries a fifth of the world’s cervical cancer burden, with 1.23 lakh new cases and 67,000 deaths per year. According to government analysis, by producing antibodies against HPV, this vaccination prevents strains 6, 11, 16 and 18.
According to officials, CERVAVAC qHPV vaccination has shown a strong antibody response against all targeted HPV types in both dose and age groups, which is about 1,000 times higher than baseline.
Prakash Kumar Singh, Director of Government and Regulatory Affairs at Serum Institute, applied to DCGI seeking market authorization of qHPV after the completion of Phase II and III clinical trials with the support of Department of Biotechnology, DCGI approval Came after a recommendation. Subject Expert Committee (SEC) of CDSCO on COVID-19 on 15th June.
According to DBT representatives, the new vaccine is based on VLPs (virus-like particles), like the hepatitis B vaccination, and is designed to protect against the HPV virus by producing antibodies against the L1 protein. According to DBT, indigenous vaccination will prove to be cheap and accessible.
Cervical cancer is one of the top three most prevalent cancers among women in India, which is one of those rare tumors where a virus is actually the cause. This virus, called human papillomavirus, results in changes in the lining of the cervix, eventually resulting in cancer. The virus is highly contagious and is spread between men and women through sexual contact.
Cervavac, the native quadrivalent HPV vaccine manufactured by SII, provides protection against 4 of the most prevalent high-risk HPV strains, namely 6,11,16, and 18. Vaccination should ideally be administered as soon as possible, ideally not earlier than 9 years of age and no later than 26 years of age. You can still take advantage of it after the age of 26, but you should talk to your doctor first.
This vaccination can reduce the incidence of cervical cancer by more than 80% and is a more cost-effective option than foreign-grown Cervarix and Gardasil. The quadrivalent human papillomavirus vaccine (qHPV) showed high efficacy in patient populations during studies conducted by SSI and DBT as part of the vaccine development process.
In 85-90% of cases, the vaccine was found to prevent cervical cancer. According to Dr N K Arora, chairperson of the National Technical Advisory Group’s COVID Working Group, “If we pass it on to our young children and daughters, they are protected from infection and, as a result, probably don’t get cancer after 30 years.” ” On Immunization (NTAGI), who was speaking about the effectiveness of the vaccine. In addition, he hoped that someday the vaccine would be included in the government’s national immunization program for women aged 9 to 14.
Disclaimer: This material, including advice, provides general information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your doctor for more details. clever read does not take responsibility for this information.